Breast cancer is classified into five main stages, numbered 0 through IV, based on how large the tumor is, whether it has reached nearby lymph nodes, and whether it has spread to distant organs. Each stage reflects how far the cancer has progressed, and it directly shapes the treatment plan and expected outcome. The five-year survival rate ranges from nearly 100% for cancer caught at an early, localized stage down to about 34% when the cancer has spread to distant parts of the body.
How Staging Works
Doctors assign a stage using what’s called the TNM system. T describes the size and extent of the primary tumor. N indicates whether cancer cells have reached nearby lymph nodes. M records whether the cancer has metastasized, meaning it has traveled to distant organs. Each letter gets a number or designation, and those three scores combine to produce an overall stage from 0 to IV.
Two types of staging happen at different points. Clinical staging is based on physical exams and imaging done before any surgery. Pathological staging comes after surgery, when a pathologist examines the removed tissue under a microscope. Pathological staging is generally more precise because it includes details that imaging alone can miss.
Beyond tumor size and spread, biological characteristics of the cancer also influence the final stage grouping. These include whether the cancer cells have hormone receptors (for estrogen or progesterone), whether they overproduce a growth-promoting protein called HER2, and how abnormal the cells look under a microscope (tumor grade). A cancer that is hormone-receptor positive, for example, may be assigned a lower prognostic stage than one of the same size that lacks those receptors, because it typically responds better to treatment.
Stage 0: Non-Invasive
Stage 0 is the earliest possible classification. The most common form is ductal carcinoma in situ (DCIS), where abnormal cells are found inside a milk duct but have not broken through the duct wall into surrounding breast tissue. Because the cells lack the ability to invade nearby tissue at this point, Stage 0 is considered non-invasive or preinvasive. It is not life-threatening on its own, but without treatment it can progress to invasive cancer over time. Treatment typically involves removing the affected area, sometimes followed by radiation to reduce the chance of recurrence.
Stage I: Small and Localized
At Stage I, the cancer has become invasive, meaning cells have broken out of the duct or lobule into surrounding breast tissue, but the tumor is still small and confined to the breast area. Stage I is split into two subcategories:
- Stage IA: The tumor is up to 2 centimeters across (roughly the size of a peanut) and has not spread to any lymph nodes.
- Stage IB: Small clusters of cancer cells, no larger than 2 millimeters, are found in nearby lymph nodes, with either no tumor in the breast or a tumor no larger than 2 centimeters.
Stage I breast cancer has an excellent prognosis. SEER data, drawn from cancer registries across the United States, show a five-year relative survival rate of 100% for localized breast cancer, a category that encompasses both Stage I and some Stage II cases.
Stage II: Larger Tumor or Limited Node Spread
Stage II means the cancer is still relatively contained but has grown larger, reached a small number of lymph nodes, or both. It splits into two groups:
- Stage IIA: No tumor is found in the breast but cancer is present in one to three underarm lymph nodes, or the tumor is 2 centimeters or smaller and has spread to underarm lymph nodes, or the tumor is between 2 and 5 centimeters but lymph nodes are clear.
- Stage IIB: The tumor is between 2 and 5 centimeters and cancer is found in one to three underarm lymph nodes, or the tumor is larger than 5 centimeters but lymph nodes are not involved.
To determine whether lymph nodes are affected, doctors often use a sentinel lymph node biopsy. A tracer substance is injected near the tumor, and it flows to the first lymph node (the sentinel node) that would receive drainage from the tumor site. That node is removed and examined under a microscope. If no cancer cells are found there, the remaining nodes are very likely clear, and no further node removal is needed. If cancer is present, additional nodes may be removed and the staging classification adjusts accordingly.
Stage III: Locally Advanced
Stage III breast cancer has spread more extensively within the breast region but has not yet reached distant organs. It is divided into three subcategories that reflect progressively wider local involvement.
- Stage IIIA: Cancer is found in four to nine underarm lymph nodes or in lymph nodes near the breastbone, with a tumor of any size. Alternatively, the tumor is larger than 5 centimeters and cancer has spread to one to three underarm lymph nodes.
- Stage IIIB: The tumor has grown into the chest wall or the skin of the breast, causing visible changes like swelling, ulceration, or skin nodules. It may also involve up to nine nearby lymph nodes. Inflammatory breast cancer, a rare and aggressive form that causes the breast to look red and swollen, is automatically classified as at least Stage IIIB regardless of tumor size.
- Stage IIIC: Cancer has spread to 10 or more underarm lymph nodes, or to lymph nodes above or below the collarbone, or to nodes near the breastbone along with underarm nodes.
The five-year relative survival rate for regional breast cancer, which covers most Stage III cases, is 87.5%. Treatment at this stage is more intensive and commonly involves a combination of chemotherapy, surgery, and radiation, sometimes with additional targeted therapies depending on the cancer’s biological profile.
Stage IV: Metastatic
Stage IV means cancer cells have traveled through the bloodstream or lymphatic system to distant parts of the body. The most common sites where breast cancer spreads are the bones, lungs, liver, and brain. A Stage IV diagnosis can come at the time of initial detection or as a recurrence years after earlier treatment.
The five-year relative survival rate for distant-stage breast cancer is 33.8%, though this number represents an average across all patients and varies significantly depending on where the cancer has spread, the cancer’s biological subtype, and how it responds to treatment. Bone-only metastases, for instance, generally carry a better outlook than spread to the brain or liver.
Treatment for Stage IV breast cancer focuses on controlling growth, managing symptoms, and maintaining quality of life for as long as possible. The specific approach depends heavily on the cancer’s biology. Hormone-receptor-positive cancers can often be managed with hormone-blocking therapies for years. HER2-positive cancers respond to targeted drugs that block the HER2 protein. Triple-negative cancers, which lack all three common targets, rely more on chemotherapy and newer immunotherapy options.
Why the Same Stage Can Look Different
Two people with the same numerical stage can have very different experiences and outlooks. A Stage IIA tumor that is hormone-receptor positive and low grade may carry a prognosis closer to Stage I, while a Stage IIA tumor that is triple-negative and high grade behaves more aggressively. The current staging system accounts for this by incorporating biological markers into the final prognostic stage grouping, which can shift the stage up or down compared to what the tumor size and node status alone would suggest.
If multiple tumors are present in the same breast, staging is based on the largest one. The presence of additional smaller tumors is noted but does not change the T category. This means staging captures the worst-case scenario rather than an average across all tumors.
Understanding your specific stage, substage, and biological profile gives the clearest picture of what to expect. A pathology report after biopsy or surgery will include all of these details, and they collectively guide every treatment decision that follows.